Dr. Marco Brughera, DVM
Group CEO
Dr. Brughera is Group Chief Executive Officer at Leadiant Biosciences S.p.A.
Dr. Brughera has extensive experience in drug development, portfolio optimization, business development and general management particularly in the oncology and rare disease areas across several global pharmaceutical and biotech companies.
He drove the commercial revival of a lead oncology product line resulting in its successful sale to Baxalta and out-licensed the Defibrotide US rights to Jazz Pharmaceuticals. He has extensive track record of discovery, development and registration of products in Oncology and Rare Disease.
He has held several positions for the Sigma-Tau Group, including Corporate R&D Managing Director.
Marco previously served as Vice President of Preclinical Development at Nerviano Medical Sciences (NMS, and Managing Director at Accellera, an independent CRO with the NMS Group.
He initially held several senior level positions in the areas of research and development with Pharmacia, Pfizer and Farmitalia Carlo Erba.
Dr. Brughera earned his degree in Veterinary Medicine from the University of Milano. He attended Management Courses at Thunderbird American Graduate Business School at Arizona State University and MIT. He was EFPIA deputy topic leader for the ICH review of the Oncology Therapeutic Guidance, publication record includes more 60 publications/communications.
He is currently Board Member of Fennec Pharmaceuticals Inc, Exelead Inc. and Naicons. He was previously Board Member at Gentium, Soligenix and Lee’s Pharmaceutical.